Amarin Corp Plc (AMRN)

[Ajax133]

JL: I completely concur with your assessment. One caveat is
the Jupiter Trial was done by AZN and not as an FDA sponsored trial.
Their 3 prior outcomes studies all failed to show a reduction
in CVE's. The Street believes Jupiter enrollment was cherry picked
and all the data were mined in house. FDA Biostatistical analysis
was never done. I do agree on the anti inflammatory effects of V
should be the key determinant. That said, V was statistically significant in lowering CRP, and I don't recall Jupiter showing
that metric. Do you ? The bottom line of your erudite explanation does affirm FDA's Anchor decision. Thanks for your reply.